MARKET

REVB

REVB

Revelation Biosciences
NASDAQ
1.230
+0.030
+2.50%
Opening 09:30 04/01 EDT
OPEN
1.230
PREV CLOSE
1.200
HIGH
1.230
LOW
1.230
VOLUME
11.32K
TURNOVER
--
52 WEEK HIGH
44.77
52 WEEK LOW
1.060
MARKET CAP
4.58M
P/E (TTM)
-0.0514
1D
5D
1M
3M
1Y
5Y
1D
Revelation Gemini data show ‘broad effect,’ says Roth Capital
TipRanks · 1d ago
Revelation Biosciences presents additional data from Prime Clinical Study
TipRanks · 2d ago
Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
Benzinga · 2d ago
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients
Reuters · 2d ago
Weekly Report: what happened at REVB last week (0323-0327)?
Weekly Report · 2d ago
Revelation Biosciences to host fireside chat at the 38th Annual Roth Conference
Reuters · 03/24 13:00
Weekly Report: what happened at REVB last week (0316-0320)?
Weekly Report · 03/23 10:24
Revelation Biosciences Shareholders Approve Warrant Share Issuance
TipRanks · 03/19 20:51
More
About REVB
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The Company's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The Company has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Webull offers Revelation Biosciences Inc stock information, including NASDAQ: REVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REVB stock methods without spending real money on the virtual paper trading platform.